Effectiveness and Safety of Firmagon in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in the Netherlands.

Trial Profile

Effectiveness and Safety of Firmagon in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in the Netherlands.

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Aug 2015

At a glance

  • Drugs Degarelix (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms FAST-NL
  • Most Recent Events

    • 18 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Nov 2014 Planned End Date changed from 1 Dec 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov.
    • 16 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top